Boston Scientific announced a definitive agreement to acquire thrombectomy specialist Penumbra in a cash-and-stock transaction valued at approximately $14.5 billion. Under the terms, Penumbra shareholders will receive 73% of the consideration in cash and 27% in newly issued Boston Scientific shares. The acquisition significantly expands Boston Scientific’s presence in fast-growing vascular intervention markets, adding Penumbra’s portfolio of clot-removal and neurovascular repair products to BSX’s existing cardiovascular franchises. Penumbra reported preliminary fourth-quarter revenue growth of 21–24%, underscoring the strategic rationale and expected contribution to Boston Scientific’s top-line growth trajectory.

On January 14, Citigroup upgraded its recommendation on Boston Scientific to “Buy,” citing the company’s continued execution on margin expansion and its evolving product mix. Analysts noted that higher-margin electrophysiology and WATCHMAN franchise growth has driven a notable uptick in adjusted operating margins over the past two quarters. With hospitals increasing capital expenditures and procedural volumes normalizing after pandemic-related deferrals, BSX’s shift toward premium devices is delivering more stable cash flows and enhancing return on invested capital.

Boston Scientific also announced a definitive agreement to acquire Valencia Technologies Corporation, a private developer of implantable neurostimulation solutions for bladder dysfunction. Valencia’s proprietary eCoin System, designed to treat overactive bladder symptoms in roughly 30 million U.S. adults, complements BSX’s existing urology portfolio. Management expects the deal to accelerate penetration in a high-unmet-need market segment and to deliver mid-single-digit percentage accretion to adjusted earnings per share within two years of closing.